Thoratec Misses on Both Revenue and Earnings
Thoratec (NAS: THOR) reported earnings on May 2. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 30 (Q1), Thoratec missed estimates on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue dropped. Non-GAAP earnings per share dropped significantly. GAAP earnings per share dropped significantly.
Gross margins expanded, operating margins contracted, net margins shrank.
Thoratec notched revenue of $117.7 million. The 17 analysts polled by S&P Capital IQ expected to see net sales of $122.5 million on the same basis. GAAP reported sales were 7.1% lower than the prior-year quarter's $126.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.41. The 17 earnings estimates compiled by S&P Capital IQ predicted $0.46 per share. Non-GAAP EPS of $0.41 for Q1 were 20% lower than the prior-year quarter's $0.51 per share. GAAP EPS of $0.31 for Q1 were 28% lower than the prior-year quarter's $0.43 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 70.2%, 90 basis points better than the prior-year quarter. Operating margin was 19.9%, 930 basis points worse than the prior-year quarter. Net margin was 15.4%, 470 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $123.0 million. On the bottom line, the average EPS estimate is $0.44.
Next year's average estimate for revenue is $499.7 million. The average EPS estimate is $1.81.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 150 members out of 173 rating the stock outperform, and 23 members rating it underperform. Among 47 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 38 give Thoratec a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Thoratec is outperform, with an average price target of $40.19.
Is Thoratec the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Thoratec to My Watchlist.
The article Thoratec Misses on Both Revenue and Earnings originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.